series-a
Stage
1
Investors
About
Lutris Pharma is a clinical-stage biopharmaceutical company developing a novel topical B-RAF inhibitor gel, LUT014, to treat skin toxicities such as acneiform rash caused by cancer therapies, aiming to improve treatment tolerability and patient quality of life.
Explore Lutris Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.